News Article | April 8, 2016
The next target of Volvo's "Drive Me" program that aims to introduce self-driving cars in the year 2020 is populous China. This "Drive Me" initiative will lead with the company's XC90 car models that will test out a number of advanced technologies that promote safety measures and autonomous driving. A "360 Surround View," that enables the car to sense the environment around it; an "Adaptive Cruise Control" that adjusts the car's speed; Volvo's "Pilot Assist Technology" and the "Lane Keeping Aid" that make sure the car stays on the right path; a "Driver Alert Control" that will monitor its driver's state; and a "City Safety" feature that will adapt the car's mobility in urban cases. To analyze the capabilities of their current tech, Volvo, now owned by China's Zhejiang Geely Holding Group Co., has chosen China as another testing ground. Another experiment will be conducted in Gothenburg, Sweden, in the next year. The company has no official announcements yet as to when the project will commence in China. These experiments will use 100 XC90 units, driven by chosen civilians, in pre-determined routes the company has mapped out and concluded to be safe areas for testing. Erik Coelingh, Senior Technical Leader for Safety and Driver Support Technologies for Volvo, states that it is not enough for the company's engineers to solely assess the features of their technology in closed areas. He believes that to fully explore the complete range of their initiative, the company has to work with civilians, "ordinary and real people" from around the globe. These individuals will not only test out the car's advanced driving technology but will also give feedbacks on whether or not they feel secure and comfortable in the automated vehicle. These chosen individuals will be picked based on the regular routes they take that complies with the company's pre-determined routes. The car will notify its driver that it can begin its autonomous driving once participants reach the area. As the car finally reaches the end of the route, it will notify its driver again to take over driving. Coelingh adds that companies have to understand the different driving situations prevalent in unique regions around the globe if we want to arrive at an age of self-driving cars. Just because cars work well in a certain region, that is, Gothenburg, doesn't mean they will produce the same results in another area like Beijing or London. China was chosen because of its populous urban statistics and the prevalent heavy road traffic, "brutal air pollution, and more than 200,000 traffic-related deaths each year." © 2016 Tech Times, All rights reserved. Do not reproduce without permission.
J.L. Becker, a Gasbarre Furnace Group Co., Plymouth, Mich., recently shipped a car bottom furnace equipped with a 4.5 x 8 x 4-ft. work zone capable of handling an 8000-lb. load with a maximum operating temperature of 1900°F. Designed for a proprietary coating process, the furnace was custom designed for a large midwestern aerospace company and its specific needs. Furnace capabilities include stress relief, hardening, tempering, and preheating.. Becker has manufactured a full line of industrial heat treating equipment for over 40 years, including design, construction and service. The equipment includes both batch and continuous systems and specializes in Integral Quench (IQ), Tip Up, Box and Car Bottom furnaces, as well as a full line of replacement parts and auxiliary equipment, including atmosphere generators, quench tanks and charge cars.
News Article | September 6, 2016
Autonomous Cars - Five Things To Know About Self Driving Cars Volvo and Autoliv recently announced that they will join forces to roll out autonomous driving software as carmakers across the globe race to embrace the self-driving systems. In separate statements, the two Swedish companies confirmed that the new enterprise would start with a work force made from 200 staff belonging to both parent companies. On the medium term, the joint venture's number of employees will reach more than 600 workers. Volvo and Autoliv aim to have their partnership's headquarters in Gothenburg, Sweden, but the new entity still lacks a name. What is known, however, is that it will deliver autonomous drive (AD) and advanced driver assistance systems (ADAS) that will first be deployed in Volvo Cars. Insiders from the companies point out that the technology should start rolling out at the debut of 2017, and note that Autoliv maintains the right to sell it to global vehicle manufacturers. The revenue obtained from this side of the business will be shared with Volvo, sources say. Håkan Samuelsson, Volvo Cars' Chief Executive, points out that by merging the resources and know-how of the two companies, the new entity has all the assets to become "a world leader in AD software development." He adds that one immediate advantage would be that new technology could reach customers way faster than before. Volvo's partnership with Autoliv is the latest in the carmaker's initiatives to secure a leading role for itself in an industry where self-driving technology is becoming commonplace. In August, Uber and Volvo signed a deal for $300 million to create a fleet of self-driving cars. To boost the efforts in this direction, Volvo announced that it is planning to bring 400 engineers on board, with most of them taking jobs in software development. This is one of the most consistent recruitment moves of the Swedish car company. Meanwhile, Autoliv and Volvo said that the first ADAS products sprouting from their cooperation should be available for purchase in 2019, with AD technology expected to hit the streets by 2021. Volvo Cars made a name for itself for being one of the safest car builders in the world. The company is keeping true to its creed of crafting world-leading active and passive safety systems. Insiders from the carmaker affirmed that the medium to long-term goal of the company is to have no victim or serious injury involving new Volvo cars by 2020. Volvo is part of the Chinese Zhejiang Geely Holding Group Co. © 2016 Tech Times, All rights reserved. Do not reproduce without permission.
News Article | August 10, 2015
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT:BTX) today announced that 27 new patents have issued during the first half of 2015 that are owned or licensed to BioTime or its subsidiaries. These new patents add to the portfolio of over 700 issued and pending patents and patent applications world wide that are owned or licensed to BioTime or its subsidiaries. The new patents include seven new U.S. patents, as well as 20 additional patents issued in Europe, Japan, Canada and Singapore. “As a leader in regenerative medicine, the BioTime family of companies commands the largest known patent estate covering the therapeutic uses of pluripotent stem technology. BioTime has worked diligently to strengthen this portfolio to protect our therapeutic programs from unfair competition and drive value in corporate alliances,” said Michael D. West, Ph.D. BioTime’s Chief Executive Officer. Select examples of new patents issuing in the United States include: BioTime, Inc., a pioneer in regenerative medicine, is a clinical-stage biotechnology company. BioTime and its subsidiaries are leveraging their industry-leading experience in pluripotent stem cell technology and a broad intellectual property portfolio to facilitate the development and use of cell-based therapies and gene marker-based molecular diagnostics for major diseases and degenerative conditions for which there presently are no cures. The lead clinical programs of BioTime and its subsidiaries include OpRegen®, currently in a Phase I/IIa trial for the treatment of the dry form of age-related macular degeneration; AST-OPC1, currently in a Phase I/IIa trial for spinal cord injuries; Renevia™, currently in a pivotal trial in Europe as an injectable matrix for the engraftment of transplanted cells to treat HIV-related lipoatrophy; and PanC-Dx™ cancer diagnostics, nearing the completion of initial clinical studies for the detection of lung, bladder, and breast cancers. AST-VAC2, a cancer vaccine, is in the pre-clinical trial stage. BioTime’s subsidiaries include the publicly traded Asterias Biotherapeutics, Inc. (NYSE MKT: AST), developing pluripotent stem cell-based therapies in neurology and oncology, including AST-OPC1 and AST-VAC2; Cell Cure Neurosciences Ltd., developing stem cell-based therapies for retinal and neurological disorders, including OpRegen®; OncoCyte Corporation, developing PanC-Dx™ cancer diagnostics; LifeMap Sciences, Inc., developing and marketing an integrated online database resource for biomedical and stem cell research; LifeMap Solutions, Inc., a subsidiary of LifeMap Sciences, developing mobile health (mHealth) products; ES Cell International Pte Ltd, which has developed cGMP-compliant human embryonic stem cell lines that are being marketed by BioTime for research purposes under the ESI BIO branding program; OrthoCyte Corporation, developing therapies to treat orthopedic disorders, diseases, and injuries; and ReCyte Therapeutics, Inc., developing therapies to treat a variety of cardiovascular and related ischemic disorders. BioTime common stock is traded on the NYSE MKT under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+. Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements. To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com